Curative members can now screen for multiple cancers with Galleri

Curative is excited to provide eligible members and dependents access to the innovative Galleri® multi-cancer early detection test from GRAIL.

Galleri is the first-of-its-kind test that looks for a signal shared by more than 50 types of cancer with a single blood test.1

Curative members and dependents must meet the eligibility requirements for this program.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Roger testimonial

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Key benefits of the Galleri test

hourglass icon

Screening for more cancers

Added to recommended screening, the Galleri test improves your chance to find cancer early. It detects a signal shared by dozens of cancers including many that don't have screening tests.1

stethoscope icon

Testing with ease

Screen with a simple blood draw easily added to your cancer screening plan.

No fasting or preparation required.

Test requires a prescription from an independent telemedicine provider

blue test result icon

Actionable results

If a cancer signal is found, results can predict the tissue type or organ associated with the cancer signal. This helps your healthcare provider guide next steps to determine if cancer is present.1

The Galleri test looks for a signal associated with active cancer and does not predict your future genetic risk for cancer. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. False positive and false negative results do occur. Galleri should be used in addition to screening tests your healthcare provider recommends.

Who is eligible?

All Curative members and their dependents must meet the following eligibility requirements as determined for this program. The cost of the test is included as part of this program once your annual Baseline Visit is completed.

Eligibility requirements

  • Active Curative plan members residing in the United States who have also completed their annual Baseline Visit
  • Aged 50 years old and older
  • Not currently pregnant
  • Not currently undergoing active cancer treatment, though history of cancer* with treatments completed at least 5 years ago is permitted
* excludes basal or squamous cell carcinoma of the skin

† No out-of-pocket costs contingent on completion of your Curative Baseline Visit within 120 days of plan activation date. If the Baseline Visit is not completed within the first 120 days of plan activation date, members completing the test after that time period will be subject to the full price of the Galleri test ($899).

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

Our testing process

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Complete your Curative Baseline Visit

Meet with your Care Navigator and a Curative Clinician for an individualized, preventive care plan and ensure you receive no copays and no deductibles for in-network care.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Request the test

After your Baseline Visit is completed, eligible members can create a Galleri portal account and complete an online test request which includes questions about your medical history (about 10 minutes).

An independent telemedicine provider will review your request.

illustrated graphic of a white, gray haired female patient having her blood drawn

Receive a collection kit and provide your sample

If the telemedicine physician confirms you're eligible and that Galleri is appropriate for you, they will order the test.

You can schedule a blood draw at a GRAIL blood draw partner and we will ship you a Galleri collection kit for your appointment. The trained technician that draws your blood sample will ship the kit back to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

The telemedicine provider will reach out and share your results when it is ready — about 2 weeks after your blood draw sample arrives at the GRAIL lab.

† No out-of-pocket costs contingent on completion of your Curative Baseline Visit within 120 days of plan activation date. If the Baseline Visit is not completed within the first 120 days of plan activation date, members and dependents completing the test after that time period will be subject to the full price of the Galleri test ($899).

What is the Galleri test?

Galleri is the first-of-its-kind multi-cancer early detection test—a test that looks for a signal shared by more than 50+ types of cancer with a single blood test. It is a screening test and does not diagnose cancer, further testing is required to confirm cancer.

illustrated video poster of the Galleri test sitting on a table in an examination room with an anatomy poster on the wall behind it

What do Galleri test results mean?


What does a “No Cancer Signal Detected” result mean?

The Galleri test looked for a cancer signal in your blood sample and did not find one.

In a clinical study, less than 2% of individuals with a No Cancer Signal Detected result had cancer.1,2

This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. This result does not predict whether you will develop cancer in the future.

Cancer signal not detected thumb

NEXT STEPS

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur as this could lead to a delayed diagnosis.

What does a “Cancer Signal Detected” result mean?

The Galleri test looked for a cancer signal in your blood sample and found one. About 1 out of every 100 tests has a Cancer Signal Detected result.2*

This result will also include one or two predictions of the tissue type or organ associated with the cancer signal, called ​"Cancer Signal Origin."

In a clinical study, around 4 out of 10 people with this result were diagnosed with cancer after diagnostic testing.2


*In the PATHFINDER study2, out of 6,578 participants tested with Galleri, 58 had a Cancer Signal Detected result.

cancer signal origin image

Other: Anus, Bone and Soft Tissue, Head and Neck, Lymphoid Lineage, Melanocytic Lineage, Myeloid Lineage, Neuroendocrine Cells of Lung or other Organs, Plasma Cell Lineage, Thyroid Gland, Uterus.

Cancer signal detected thumb

NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer.

† No out-of-pocket costs contingent on completion of your Curative Baseline Visit within 120 days of plan activation date. If the Baseline Visit is not completed within the first 120 days of plan activation date, members and dependents completing the test after that time period will be subject to the full price of the Galleri test ($899).

Frequently Asked Questions

All Curative members and their dependents must meet the following eligibility requirements as determined for this program. The cost of the test is included as part of this program once your annual Baseline Visit is completed.

  • Active Curative plan members residing in the United States who have also completed their annual Baseline Visit
  • Aged 50 years old and older
  • Not currently pregnant
  • Not currently undergoing active cancer treatment, though history of cancer* with treatments completed at least 5 years ago is permitted

† No out-of-pocket costs contingent on completion of your Curative Baseline Visit within 120 days of plan activation date. If the Baseline Visit is not completed within the first 120 days of plan activation date, members completing the test after that time period will be subject to the full price of the Galleri test ($899).

* excludes basal or squamous cell carcinoma of the skin

To access the Galleri test as a covered offering, you must first complete your annual Curative Baseline Visit.

Once your Baseline Visit is complete, you can request the test through an independent telemedicine healthcare provider via the test request process on Galleri.com/curative.

The independent telemedicine provider will review your request and order the test, if appropriate. The test is prescription only.

Please use your Curative Member ID number on your card.

Yes, if you have a history of cancer, you must not currently be receiving active cancer treatment and you must have completed cancer treatment at least 5 years ago.*

* excludes basal or squamous cell carcinoma of the skin

Once each member’s Curative Baseline Visit is complete, the cost of the Galleri test, blood draw, and laboratory fees are all coveredunder your Curative plan for eligible members and dependents.

An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you at Galleri.com/schedule.

Please note, the blood draw associated with Galleri must occur on a date you are covered under this offering. Members are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after their Curative plan coverage has ended.

† No out-of-pocket costs contingent on completion of your Curative Baseline Visit within 120 days of plan activation date. If the Baseline Visit is not completed within the first 120 days of plan activation date, members completing the test after that time period will be subject to the full price of the Galleri test ($899).

GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. GRAIL is the company that manufactures the Galleri multi-cancer early detection test. You may receive information or communications from GRAIL or Galleri about your benefit or the Galleri test.

Under this program, eligible Curative members and eligible dependents will be able to complete the Galleri test every 12 months.

To access the Galleri test as a fully covered offering, you must first complete your annual Curative Baseline Visit. Once completed, eligible members and dependents must request the test through an independent telemedicine healthcare provider via the test request process on Galleri.com/curative.

Please note, the blood draw associated with Galleri must occur on a date you are covered under this offering. Members are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after their Curative plan coverage has ended.

As part of this program, eligible Curative members and eligible dependents are each limited to one Galleri test during a 12-month period.

The Galleri test is a multi-cancer early detection test that screens for a signal shared by more than 50 types of cancer – many that lack recommended screening – through a simple blood draw. Galleri is a screening test and does not diagnose cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood.

Every time you take the test, Galleri checks more than 100,000 DNA regions and over a million specific DNA sites to screen for a signal shared by multiple cancers. If a cancer signal is detected, results from the test can predict the tissue type or organ associated with the cancer signal. This information helps guide healthcare providers to perform a diagnostic evaluation for cancer.

The Galleri test looks for active cancer and does not predict future genetic risk for cancer

Cancer risk increases for everyone as they age, regardless of family history—only 5% to 10% of cancers are inherited.

Age is the biggest risk factor for cancer. In fact, adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50

In a clinical study, Galleri detected a signal shared by over 50 types of cancer —including some fast-spreading and aggressive cancers responsible for approximately two-thirds of cancer deaths. Galleri is a cancer screening test, meaning it looks for cancer before symptoms appear. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Please note, if you are interested in requesting the Galleri test please be sure to return to this landing page and start the process at Galleri.com/curative.

A “Cancer Signal Detected” result is expected in approximately 1% or 1 out of 100 Galleri tests in people over 50 years of age.

One of the ways we measure test accuracy is with Positive Predictive Value (PPV). PPV is the probability that a person with a “Cancer Signal Detected” test result truly has cancer.

In a recent clinical study, on average, 4 out of 10 people with a "Cancer Signal Detected" result received a cancer diagnosis with diagnostic testing, and 1 out of 200 people without cancer received a "Cancer Signal Detected" result.

(Positive Predictive Value was 43% and False Positive rate was 0.5%)

A False Positive is a test result that indicates that a person has a specific disease or condition when the person actually does not have the disease or condition.

No, Galleri is not a genetic risk assessment test. A genetic risk assessment is a one time only measurement and assesses your future risk of developing cancer. The Galleri test looks for a signal associated with active cancer at the time of your blood draw. Genetic tests may look at DNA and assess lifelong risk for cancer but cannot detect if a person currently has cancer.

Our goal is for Galleri to be a routine cancer screening test. By regularly using the Galleri test alongside recommended cancer screenings, you can increase your chance of finding cancer early.

No, the Galleri test is only commercially available in the US.

The Galleri test has not been cleared or approved by the FDA. Galleri is a Laboratory Developed Test. GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The GRAIL clinical laboratory also holds a New York Department of Health Clinical Laboratory Evaluation Program (CLEP) permit.

Schedule a time and place convenient for you. Visit: Galleri.com/schedule to select either:

  • A GRAIL partner lab

  • A mobile phlebotomy option.
    • A trained technician will come to your home, office, or any preferred location to complete your blood draw

Learn more about how your sample is processed at the GRAIL laboratory by watching this video.

Please note, if you are interested in requesting the Galleri test please be sure to return to this landing page and start the process at Galleri.com/curative.

Once you receive your sample collection kit, please do not break the quality seal on it. The collection kit should be opened by the trained technician who draws your blood sample.

Store the kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, do not store the collection kit in a car.

To schedule your blood draw visit: Galleri.com/schedule.

Bring your unopened Galleri specimen collection kit and your completed and printed “Test Requisition Form” you received from the telemedicine provider to your blood draw appointment.

You will receive these items if your eligibility for the Galleri test is approved.

  • A Galleri specimen collection kit will be mailed to you within one week after your request is approved. Do not break the quality seal on the specimen collection kit. It should be opened by the lab technician who draws your blood sample.
  • A completed Test Requisition Form will be emailed to you from the ordering telemedicine provider. Remember to print the form and bring it to your appointment.

The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing. Everything needed to complete the blood and return the sample is within the Galleri kit.

If you or your blood draw technician has questions, please call GRAIL Customer Service: (833) 694‑2553

No fasting or preparation is required for the Galleri test.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes typically from a vein in your arm.

If you no longer wish to receive your Galleri results, please contact your ordering healthcare provider to request a cancellation. If you are not able to reach your healthcare provider or require further assistance, please contact GRAIL Customer Service by filling out a support request or calling 833-694-2553.

Your sample will arrive at the GRAIL lab one to two business days after your blood draw. Test results will be available about two weeks after your sample is received at the GRAIL lab.

Your test results can be requested by contacting GRAIL Customer Service by filling out a support request or calling 833-694-2553.

The Galleri test detected a signal often associated with cancer. This result will also include one or two predictions of the tissue type or organ associated with the cancer signal, called ​“Cancer Signal Origin.”

Results should be interpreted by a healthcare provider. This test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

False positive results do occur.

The Galleri test looked for a cancer signal in your blood sample and did not find one. A Galleri result of No Cancer Signal Detected does not rule out cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Continue with routine cancer screenings your healthcare provider recommends. This result does not predict whether you will develop cancer in the future.

False negative results do occur.

The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early. Using Galleri in addition to recommended single-cancer screenings can increase your chances of finding cancer early, when there may be more treatment options.

Galleri does not detect a signal for all cancers and not all cancers can be detected in the blood.

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

All results are automatically shared with the independent telemedicine provider who ordered the test.

If you would like GRAIL to fax your results to an additional healthcare provider, please contact GRAIL Customer Service by calling 833-694-2553 to receive instructions on how to complete a results release form.

The healthcare provider who orders the test will receive your test result and share it with you. Your test result and medical information are confidential, and access is limited to individuals who need the information for a specific purpose, such as the ordering provider. The ordering provider will help you understand your test results and determine your next steps.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service at 833−694−2553 or by email at customerservice@​grail.​com

For questions regarding your Curative plan, please contact Member Services via the phone number listed on the back of your Curative Member ID card.

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI: https://doi.org/10.1016/j.annonc.2021.05.806.

  2. Schrag D, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-60. DOI: https://doi.org/10.1016/S0140-6736(23)01700-2.